Proactive Investors - Run By Investors For Investors

MaxCyte doses first phase I patient

The dose-escalation study is taking place in the US
image of a t-cell
MCY-M11 is what’s known as a chimeric antigen receptor, or CAR therapy, which gives T-cells the new ability to target a specific protein.

MaxCyte PLC (LON:MXCT) said the first patient had been dosed with its experimental targeted treatment for cancer.

MCY-M11 is what’s known as a chimeric antigen receptor, or CAR therapy, which gives T-cells the new ability to target a specific protein.

T-cells are part of the immune system and circulate around our bodies, scanning for cellular abnormalities and infections.

Ovarian cancer targeted 

MCY-M11 is a mesothelin targeting CAR that will be used to treat ovarian cancer and peritoneal mesothelioma, which forms around the tissue lining of the womb.

A total of 15 women with relapsed or hard-to-treat forms of the disease will receive the drug, which is being assessed primarily for safety and whether it is well tolerated by those taking it.

"The initiation of patient dosing in our first clinical trial with our lead CAR therapeutic candidate is a significant milestone for MaxCyte, validating our streamlined manufacturing process for clinical use," said MaxCyte chief executive Doug Doerfler.

"We are extremely pleased to have very experienced investigators at two leading clinical centres conducting this study in solid tumours.

“We believe this clinical trial will further demonstrate the potential of our proprietary CARMA (CAR therapeutic) autologous cell-therapy platform to develop meaningful, targeted cell-based immune therapies."

 

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018
Article
October 10 2018

Related Articles

eye
November 19 2018
“It’s a blended model of highly cash generative assets and top line growth”
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
researcher filling a tray of samples
Fri
The company has two clinical trials underway and is well funded to achieve its immediate ambitions

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use